A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
Ito K, Morise M, Wakuda K, Hataji O, Shimokawaji T, Takahashi K, Furuya N, Takeyama Y, Goto Y, Abe T, Kato T, Ozone S, Ikeda S, Kogure Y, Yokoyama T, Kimura M, Yoshioka H, Murotani K, Kondo M, Saka H.
Ito K, et al. Among authors: kato t.
ESMO Open. 2021 Jun;6(3):100115. doi: 10.1016/j.esmoop.2021.100115. Epub 2021 May 10.
ESMO Open. 2021.
PMID: 33984681
Free PMC article.